Keudell Morrison Wealth Management Makes New Investment in Johnson & Johnson $JNJ

Key Points

• Keudell Morrison Wealth Management opened a new position in Johnson & Johnson in the fourth quarter, buying 8,722 shares valued at about $1.8 million.
• Johnson & Johnson continues to attract institutional support, with several large asset managers increasing holdings; overall, 69.55% of the stock is owned by institutions and hedge funds.
• The company has recent positive momentum from both operations and Wall Street views: nipocalimab was approved in China, a new coronary catheter was unveiled, and analysts maintain a Moderate Buy consensus with a $253.04 price target.

Keudell Morrison Wealth Management acquired a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 8,722 shares of the company's stock, valued at approximately $1,805,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock worth $49,740,362,000 after buying an additional 3,731,074 shares during the period. Wellington Management Group LLP lifted its position in Johnson & Johnson by 3.8% during the third quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company's stock valued at $4,789,914,000 after purchasing an additional 956,239 shares during the period. Bank of New York Mellon Corp lifted its position in Johnson & Johnson by 3.5% during the third quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company's stock valued at $4,568,313,000 after purchasing an additional 835,146 shares during the period. Legal & General Group Plc lifted its position in Johnson & Johnson by 2.8% during the third quarter. Legal & General Group Plc now owns 19,450,064 shares of the company's stock valued at $3,606,431,000 after purchasing an additional 532,790 shares during the period. Finally, Amundi lifted its position in Johnson & Johnson by 19.3% during the third quarter. Amundi now owns 13,354,936 shares of the company's stock valued at $2,512,719,000 after purchasing an additional 2,163,838 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

JNJ has been the subject of a number of recent analyst reports. Barclays lifted their price objective on shares of Johnson & Johnson from $234.00 to $255.00 and gave the company an "equal weight" rating in a report on Wednesday, April 15th. TD Cowen initiated coverage on shares of Johnson & Johnson in a report on Wednesday, April 8th. They issued a "buy" rating and a $250.00 price objective for the company. Loop Capital set a $220.00 price objective on shares of Johnson & Johnson in a report on Tuesday, January 27th. Citigroup lifted their price objective on shares of Johnson & Johnson from $274.00 to $285.00 and gave the company a "buy" rating in a report on Tuesday, April 7th. Finally, Johnson Rice raised shares of Johnson & Johnson from a "hold" rating to an "outperform" rating in a report on Wednesday, May 13th. Twenty equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $253.04.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson said its immunology drug nipocalimab was approved in China, expanding the company’s international growth opportunity and adding to its pipeline momentum. Reuters: Johnson & Johnson says nipocalimab approved in China
• Positive Sentiment: The company unveiled the Shockwave C2 Aero Coronary IVL Catheter, a next-generation device for calcified coronary artery disease, reinforcing growth in its medtech division and showing continued product innovation. Yahoo Finance: Johnson & Johnson (JNJ) Unveils Next-Gen Catheter for Coronary Artery Disease
• Positive Sentiment: Reports highlighting Johnson & Johnson as a defensive growth stock and a top long-term pick may be supporting sentiment, especially as investors look for steadier names amid market volatility. Insider Monkey: Why Johnson & Johnson (JNJ) Still Fits a Defensive Growth Case
• Neutral Sentiment: Several market commentaries and stock reports referenced J&J alongside other dividend and healthcare names, but these pieces did not provide new company-specific catalysts. Yahoo Finance: Johnson & Johnson Outperforms Broader Market

Johnson & Johnson Stock Up 1.0%

JNJ stock opened at $231.69 on Friday. The stock has a market capitalization of $557.73 billion, a P/E ratio of 26.79, a P/E/G ratio of 2.25 and a beta of 0.27. The firm has a 50-day simple moving average of $234.19 and a 200-day simple moving average of $223.20. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 52 week low of $149.04 and a 52 week high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company's quarterly revenue was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson's dividend payout ratio is presently 60.12%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.